

Message

From: Riaz Zaman [rzaman@paint.org]
Sent: 1/9/2020 9:05:05 PM
To: Corado, Ana [Corado.Ana@epa.gov]
Subject: ACA inquiry re: study regarding acute exposure to NMP

Dear Dr. Corado,

In reaching a conclusion of unreasonable risk while using NMP in formulations (such as paint), EPA relies on information provided by Exxon, "Multigeneration Rat Reproduction Study with N-Methylpyrrolidone, Project Number 236535." HERO site information is: https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/3809420.

Do you know if this information is CBI or is it available through EPA? Please advise.

In addition, I am wondering if you can tell me about the acute exposure scenario generally. What are the parameters for acute exposure that EPA considered? Or more generally, what does EPA mean by acute exposure as used in the NMP risk evaluation (EPA has not described relevance of acute exposure or parameters).

I am trying to understand EPA's conclusions, since it issues a finding of *no unreasonable risk* for chronic exposure during formulation with NMP, but identified *unreasonable risk* for acute exposures during formulation with NMP.

I appreciate your advice on this matter.

Thank you,

Riaz Zaman • American Coatings Association • Counsel, Government Affairs
202.719.3715 (o) | rzaman@paint.org | www.paint.org